Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

Introduction: Extensive-stage SCLC (ES-SCLC) is a highly aggressive type of lung cancer with a high risk of early progression and limited survival. Standard of care for first-line treatment is platinum-etoposide chemotherapy plus anti–PD-L1 immune checkpoint inhibitors. Methods: Intergroupe Francoph...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lionel Falchero, MD, Karim Amrane, MD, Benoît Godbert, MD, Bénédicte Leterre, MD, Jeannick Madelaine, MD, Pierre Fournel, MD, PhD, Céline Mascaux, MD, PhD, Judith Raimbourg, MD, Sophie Schneider, MD, Aurélie Swalduz, MD, Rémi Veillon, MD, Alexandra Langlais, MSc, Pascale Missy, PhD, Franck Morin, MSc, Virginie Westeel, MD, PhD, Nicolas Girard, MD, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-04-01
coleção:	JTO Clinical and Research Reports
Assuntos:	Immunotherapy Long-term survival long-term response SCLC
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666364326000159
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!